NCCN临床实践指南_遗传_家族高风险评估-乳腺癌和卵巢癌(2019.V3)英文版
112页1、NCCN org Version 3 2019 01 18 19 2019 National Comprehensive Cancer Network NCCN All rights reserved NCCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines Genetic Familial High Risk Assessment Breast and Ovarian Version 3 2019 January 18 2019 Continue Continue NCCN Guidelines Panel Disclosures Medical oncology Cancer Medical genetics Internal medicine Hematology Hematolo
2、gy oncology Gynecologic oncology Gynecology Breast surgical oncology 33 3124 3129 Shindo K Yu J Suenaga M et al J Clin Oncol 2017 35 3382 3390 Footnote j Eg PARP inhibitors for ovarian cancer and metastatic HER2 negative breast cancer platinum therapy for prostate cancer See the relevant NCCN treatment guidelines eg NCCN Guidelines for Breast Cancer NCCN Guidelines for Prostate Cancer for further details Footnote k This may be extended to an affected third degree relative if related through two
3、male relatives eg paternal grandfather s mother or sister Continued UPDATES BRCA Related Breast and or Ovarian Cancer Syndrome BR OV A 2 of 3 Genetic Testing Approach 3rd bullet 1st sentence was revised If no pathogenic likely pathogenic variant is found consider referral for expert genetics evaluation if not yet performed testing for other hereditary cancer syndromes may be appropriate other hereditary cancer syndromes BR OV A 3 of 3 A new section titled Evaluating the Source of Genetic Testing
4、 Information was added Updates in Version 2 2019 of the NCCN Guidelines for Genetic Familial High Risk Assessment Breast and Ovarian from Version 1 2019 include BRCA Related Breast and or Ovarian Cancer Syndrome BRCA 1 BRCA1 2 Testing Criteria Under the 2nd bullet Personal history of breast cancer one or more of the following The 1st sub bullet was revised as Diagnosed 50 46 50 y with The 3rd tertiary bullet was added 1 close blood relative with high grade Gleason score 7 prostate cancer Under t
5、he 4th sub bullet Diagnosed at any age with 1 close blood relative with The criterion was revised by removing high grade Gleason score 7 or from metastatic prostate cancer Updates in Version 3 2019 of the NCCN Guidelines for Genetic Familial High Risk Assessment Breast and Ovarian from Version 2 2019 include MS 1 The Discussion section has been updated to reflect the changes in the algorithm NCCN Guidelines Version 3 2019 Genetic Familial High Risk Assessment Breast and Ovarian Version 3 2019 01
《NCCN临床实践指南_遗传_家族高风险评估-乳腺癌和卵巢癌(2019.V3)英文版》由会员沧海****3分享,可在线阅读,更多相关《NCCN临床实践指南_遗传_家族高风险评估-乳腺癌和卵巢癌(2019.V3)英文版》请在金锄头文库上搜索。
洁厕灵企业技术标准范例
发电企业热工设备检修规程
发电企业热控日常点检标准
发电企业汽机(含燃机)技术监督细则
发电企业电气设备保护及安全自动装置投退和定值变更管理标准
继电保护定值变更通知单
继电保护及安全自动装置投退审批表
电气保护定值更改申请单
化工企业粉尘涉爆企业整体安全风险等级评估方法
化工企业安全检查管理规程
电气安全管理规程范例
农业企业绿色食品大棚生菜生产操作规程
农业企业绿色食品桃园管理规程
农业企业绿色食品早春蕹菜生产操作规程
农业企业绿色食品大棚蚕豆促早栽培生产技术操作规程
农业企业绿色食品荠菜种植规程
农业企业绿色食品青椒种植规程
农业企业绿色食品筒篙种植规程
农业企业绿色食品油麦菜种植规程
农业企业绿色食品木耳菜种植规程
2023-05-11 11页
2022-09-05 10页
2022-08-18 10页
2022-08-18 6页
2022-08-18 7页
2022-08-18 3页
2022-08-18 5页
2022-08-18 9页
2022-08-18 7页
2022-08-18 4页